Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can vibrating airways and chest walls improve sleep in COPD patients?

NCT ID NCT06274957

Symptom relief Sponsor: Saglik Bilimleri Universitesi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at two types of vibrating devices—one that sends vibrations into the airways and one that vibrates the chest wall—to see if they could help people with COPD breathe better and sleep more soundly during a sudden worsening of their condition. 33 adults with severe COPD took part. The researchers measured breathing, sleep quality, and physical function before and after using the devices.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

33 people

The number who actually took part.

Started

May 2024

Finished

Jun 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Being classified as GOLD stage 3 or 4 based on spirometric evaluation in the medical history. * Having a hospital admission within the specified time frame, evaluated by a pulmonary specialist, and admitted to the pulmonary diseases service with a diagnosis of COPD exacerbation. * Being 40 years of age or older. * Voluntarily agreeing to participate in the study. Exclusion Criteria: * Having a hospital admission with a diagnosis of asthma attack in the last 5 years. * Monitoring suspicious focal points for pneumonia on lung radiology. * Hospitalization due to reasons other than exacerbation despite having a diagnosis of COPD. * Presence of pulmonary fibrosis or suspicious findings of fibrosis on radiology. * Systemic fungal infections. * Having cognitive impairment affecting the decision to participate in the study, such as confusion, orientation disorder, or dementia. * Patients with lung cancer or metastasis in the lungs. * Diagnosis of conditions provoking shortness of breath other than COPD exacerbation, such as pneumonia, pneumothorax, heart failure, and pulmonary embolism. * Presence of a new-onset rhythm disorder or ischemic changes requiring intervention on the EKG, excluding sinus tachycardia and multifocal atrial tachycardia. * Chronic kidney failure requiring hemodialysis. * Patients with conditions causing weakness in the lower extremities, such as arthritis, neurological disease, deep vein thrombosis, peripheral artery disease, muscle weakness, fractures, osteoarthritis, etc. * Having ankylosing spondylitis with a Cobb angle of 10 degrees or more in the radiographic evaluation of the vertebral column. * Having undergone surgery on the upper extremities, lower extremities, neck, and back.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD exacerbation acute are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD exacerbation acute

Contacts and locations

Locations

  • University of Health Sciences

    Istanbul, Turkey, 34353, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.